Cargando...
Potentiation of the novel Topoisomerase I inhibitor indenoisoquinoline LMP-400 by the cell checkpoint and Chk1-Chk2 inhibitor, AZD7762
Novel topoisomerase I (Top1) inhibitors are in clinical development to circumvent the drawbacks of camptothecins. Here we report molecular investigations into LMP-400, an indenoisoquinoline Top1 inhibitor in Phase 1 clinical trial, by itself and in combination with the cell cycle checkpoint inhibito...
Guardado en:
| Autores principales: | , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2011
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3288175/ https://ncbi.nlm.nih.gov/pubmed/22189968 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-11-2579 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|